Viewing Study NCT00096655



Ignite Creation Date: 2024-05-05 @ 11:38 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00096655
Status: COMPLETED
Last Update Posted: 2011-05-17
First Post: 2004-11-12

Brief Title: A Safety and Efficacy Study for Infliximab Remicade in Patients With Ulcerative Colitis
Sponsor: Centocor Inc
Organization: Centocor Inc

Study Overview

Official Title: A Randomized Placebo-controlled Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Status: COMPLETED
Status Verified Date: 2010-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab Remicade in patients with Ulcerative Colitis Infliximab Remicade targets specific proteins in the bodys immune system to help control the development of inflammation to help reduce painful disease
Detailed Description: This study is designed to investigate the safety and effectiveness of infliximab in adult patients with active ulcerative colitis The purpose of this study is to see if the symptoms of ulcerative colitis are lessened with this medication infliximab and what dose is needed to do that safelyPatients will receive infusions of either 5 or 10 mgkg or placebo at weeks 0 2 6 14 and 22 up to week 164 Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests vital signs such as blood pressure physical examinations and the occurrence and severity of adverse events as well as other study specific procedures

Patients will receive infusions into the vein of either 5 or 10 mgkg or placebo at weeks 0 2 6 and every 8 weeks up to week 164

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None